Amphotericin B Dosing for Invasive Aspergillosis
For invasive aspergillosis in adults without renal impairment, liposomal amphotericin B (L-AmB) at 3 mg/kg/day is the recommended dose when amphotericin B is used, with treatment duration extending up to 11 months and cumulative doses up to 3.6 grams based on clinical response. 1
Primary Treatment Considerations
Amphotericin B formulations are not first-line therapy for invasive aspergillosis. Voriconazole or isavuconazole are the preferred primary agents 2. However, liposomal amphotericin B serves as an important alternative when:
- Hepatic toxicities preclude azole use
- Drug interactions warrant non-azole alternatives
- Voriconazole-resistant molds remain a concern
- Azole resistance is documented or suspected 2
Specific Dosing Recommendations
Liposomal Amphotericin B (L-AmB)
The standard dose is 3 mg/kg/day 2, 3. A randomized trial comparing 3 mg/kg/day versus 10 mg/kg/day demonstrated:
- Similar overall outcomes (50% vs 46% response rates)
- Significantly more toxicity with higher dosing (32% vs 20%)
- No benefit from dose escalation 2
Higher doses (10 mg/kg/day) are not recommended due to increased nephrotoxicity without improved efficacy 2.
Conventional Amphotericin B Deoxycholate
If conventional amphotericin B must be used (though lipid formulations are strongly preferred):
Initiation protocol:
- Test dose: 1 mg over 20-30 minutes
- Initial therapy: 0.25-0.3 mg/kg/day for patients with good cardio-renal function
- Gradual escalation: Increase by 5-10 mg/day to target dose of 0.5-0.7 mg/kg/day
- Maximum dose: 1.5 mg/kg/day (never exceed) 1
Critical safety note: Doses exceeding 1.5 mg/kg can result in potentially fatal cardiac or cardiopulmonary arrest 1.
Amphotericin B Lipid Complex (ABLC)
Dose: 5 mg/kg/day when used, though primarily studied in salvage therapy settings 2.
Treatment Duration
Duration is individualized based on clinical response but FDA labeling provides specific guidance:
- Treatment period: Up to 11 months documented 1
- Cumulative dose: Up to 3.6 grams total 1
- Continue until clinical resolution and immune reconstitution
- Pediatric data shows successful treatment with 8 weeks of high-dose L-AmB (5 mg/kg) 4
The FDA explicitly states: "There are insufficient data presently available to define total dosage requirements and duration of treatment necessary for eradication of specific mycoses" 1. This reflects the need for clinical judgment based on:
- Site and severity of infection
- Immune status and recovery
- Radiographic improvement
- Microbiological clearance
Administration Details
Infusion parameters:
- Infuse over 2-6 hours depending on dose 1
- Concentration: 0.1 mg/mL (1 mg/10 mL) 1
- Use 5% dextrose solution with pH >4.2 1
- Never use saline solutions (causes precipitation) 1
Key Clinical Pitfalls
Toxicity monitoring is essential:
- Infusion-related reactions are common in first 1-3 hours 1
- Monitor renal function, electrolytes (especially potassium and magnesium), liver function, and blood counts frequently 1
- Nephrotoxicity risk increases with concurrent nephrotoxic agents (aminoglycosides, cyclosporine, pentamidine) 1
- Hydration and sodium repletion before administration may reduce nephrotoxicity 1
Drug interactions:
- Hypokalemia from amphotericin B potentiates digitalis toxicity 1
- Corticosteroids worsen hypokalemia 1
- Avoid concurrent leukocyte transfusions (risk of acute pulmonary toxicity) 1
Treatment interruption: If therapy is stopped for >7 days, restart at lowest dose (0.25 mg/kg) and re-escalate gradually 1.
Comparative Context
While lipid formulations demonstrate reduced nephrotoxicity and fewer infusion reactions compared to conventional amphotericin B 5, 6, no mortality benefit has been consistently demonstrated in randomized trials 5. The primary advantage is improved safety profile, allowing completion of necessary treatment duration 5, 6.
In settings with high triazole resistance (>10%), empiric monotherapy with either voriconazole or L-AmB based on clinical factors has shown acceptable outcomes, with 100-day attributable mortality of 20% 7.